Details for New Drug Application (NDA): 050297
✉ Email this page to a colleague
NDA 050297 describes ERYPED, which is a drug marketed by Carnegie and Azurity and is included in two NDAs. It is available from three suppliers. Additional details are available on the ERYPED profile page.
The generic ingredient in ERYPED is erythromycin ethylsuccinate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
The generic ingredient in ERYPED is erythromycin ethylsuccinate. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.
Summary for 050297
| Tradename: | ERYPED |
| Applicant: | Azurity |
| Ingredient: | erythromycin ethylsuccinate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050297
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 200MG BASE | ||||
| Approval Date: | Jul 5, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
